Sequential injury of the rabbit abdominal aorta induces intramural coagulation and luminal narrowing independent of intimal mass: Extrinsic pathway inhibition eliminates luminal narrowing

Circulation Research

Volumn 82, Issue 9, 1998, Pages 996-1006

  Courtman, David W ^a   Schwartz, Stephen M ^a   Hart, Charles E ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ZYMOGENETICS INC   (United States)

Author keywords

Arteries; Factor VII; Fibrin; Tissue factor; Tunica intima

Indexed keywords

ABDOMINAL AORTA; ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHERECTOMY; BALLOON CATHETER; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVE SITE; ILIAC ARTERY; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0032543282     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.82.9.996     Document Type: Article

References (64)

1. Ross R. The pathogenesis of atherosclerosis a perspective for the 1990's. Nature. 1993;362:801-809.
2. O'Brien ER, Alpers CE, Stewart DE, Ferguson M, Tran N, Gordon D, Benditt EP, Hinohara T. Simpson JB, Schwartz SM. Proliferation in primary and restenotic coronary atherectomy tissue: implications for antiproliferative therapy. Circ Res. 1993;73:223-231.
3. Mintz GS, Kovach JA, Javier SP, Ditrano CJ, Leon MB. Geometric remodeling is the predominant mechanism of late lumen loss after coronary angioplasty [abstract]. Circulation 1993;88(suppl I):I-654.
4. Di Mario C, Gil R, Camenzind E, Ozaki Y, von Birgelen C, Umans V, de Jaegere P, de Feyter PJ, Roelandt JRTC, Serruys PW. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. Am J Cordiol. 1995;75:772-777.
5. Mulvaney MJ. Resistance vessel structure in hypertension: growth or remodeling. J Cardiovasc Pharmacol. 1995;22(suppl 5):s44-s47.
6. Schwartz SM, deBlois D, O'Brien ERM. The intima: soil for atherosclerosis and restenosis. Circ Res. 1995;77:445-465.
7. Schwartz SM, Murry CE, O'Brien ER. Vessel wall response to injury. Sci Med. 1996;3:12-21.
8. Berk BC, Harris K. Restenosis after percutaneous transluminal coronary angioplasty: new therapeutic insights from pathogenic mechanisms. Adv Intern Med. 1995;40:445-501.
9. Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 1982;62:347-504.
10. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371-1375.
11. Clarkson TB, Prichard RW, Morgan TM, Petrick GS, Klein KP. Remodeling of coronary arteries in human and nonhuman primates. JAMA. 1994;271:289-294.
12. Weissman NJ, Mendelsohn FO, Palacios IF, Weyman AE. Development of coronary compensatory enlargement in vivo: sequential assessment with intravascular ultrasound. Am Heart J. 1995;130:1383-1385.
13. Geary RL, Williams JK, Golden D, Brown DG, Benjamin ME, Adams MR. Time course of cellular proliferation, intimal hyperplasia, and remodeling following angioplasty in monkeys with established atherosclerosis. Arterioscler Thromb Vasc Biol. 1996;16:24-43.
14. Langille BL, O'Donnell F. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium dependent. Science. 1986;231:405-407.
15. Wilensky RL, March KL, Gradus-Pizlo I, Sandusky G, Fineberg N, Hathaway DR. Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit. Circulation. 1995;92:2995-3005.
16. Kakuta T, Currier JW, Haydenschild CC, Ryan TJ, Faxon DP. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation. 1994;89:2809-2815.
17. Post MJ, Borst C, Kuntz RE. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty. Circulation. 1994;89:2816-2821.
18. Groves HM, Kinlough-Rathbone RL, Richardson M, Jorgensen L, Moore S, Mustard JF. Thrombin generation and fibrin formation following injury to rabbit neointima. Lab Invest. 1982;46:605-612.
19. Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, Nemerson Y, Taubman MB. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest. 1993;91:2253-2259.
20. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A. 1989;86:2839-2843.
21. Jorgensen L, Grothe AG, Groves HM, Kinlough-Rathbone RL, Richardson M, Mustard JF. Sequence of cellular responses in rabbit aortas following one and two injuries with a balloon catheter. Br J Exp Pathol. 1988;69:473-486.
22. Jorgensen L, Grothe AG, Groves HM, Kinlough-Rathbone RL, Richardson M, Mustard JF. Distribution of cellular responses in rabbit aortae following one and two injuries with a balloon catheter. Br J Exp Pathol. 1988;69:351-365.
23. Hatton MWC, Moar SL, Richardson M. Deendothelialization In vivo initiates a thrombogenic reaction at the rabbit aorta surface. Am J Pathol. 1989;135:499-508.
24. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation. 1995;92:3041-3050.
25. Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood. 1993;81:734-744.
26. Gerdes C, Faber-Steinfeld V, Yalkinoglu O, Wohlfeil S. Comparison of the effects of the thrombin inhibitor r-hirudin in four animal models of neointima formation after arterial injury. Arterioscler Thromb Vasc Biol. 1996;16:1306-1311.
27. Noda-Heiny H, Sobel BE. Vascular smooth muscle cell migration mediated by thrombin and urokinase receptor. Am J Physiol 1995;37:C1195-C1201.
28. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW, Coughlin JR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest. 1993;91:94-98.
29. Ko FN, Yang YC, Huang SC, Ou JT. Coagulation factor Xa stimulates platelet derived growth factor release and mitogenesis in cultured vascular smooth muscle cells of rat. J Clin Invest. 1996;98:1493-1501.
30. Gasic GP, Arenas CP, Gasic TB, Gasic GJ. Coagulation factors X, Xa, and protein S as potent mitogens of cultured smooth muscle cells. Proc Natl Acad Sci U S A. 1992;89:2317-2320.
31. Ragosta M, Barry WL, Gimple LW, Gertz SD, McCoy KW, Stouffer GA, McNamara CA, Powers ER, Owens GK, Sarembock IJ. Effect of thrombin inhibition with desulfatohirudin on early kinetics of cellular proliferation after balloon angioplasty in atherosclerotic rabbits. Circulation. 1996;93:1194-1200.
32. Tuan TL, Song A, Chang S, Younai S, Nimni ME. In vitro fibroplasia: matrix contraction, cell growth, and collagen production of fibroblasts cultured in fibrin gels. Exp Cell Res. 1996;223:127-134.
33. Tingstrom A, Heldin CH, Rubin K. Regulation of fibroblast mediated collagen gel contraction by platelet derived growth factor, interleukin 1 alpha and transforming growth factor-beta 1. J Cell Sci. 1992;102(pt 2):315-322.
34. Xu J, Clark RA. Extracellular matrix alters PDGF regulation of fibroblast integrins. J Cell Biol. 1996;132:239-249.
35. Guirdy C. Extracellular matrix contraction by fibroblasts: peptide promoters and second messengers. Cancer Metastasis Rev. 1992;11:45-54.
36. Carver W, Molano I, Reaves TA, Borg TA, Terracio L. Role of alpha 1 beta 1 integrin complex in collagen gel contraction in vitro by fibroblasts. J Cell Physiol. 1995;165:425-437.
37. Chen JK, Haimes HB, Weinberg CB. Role of growth factors in the contraction and maintenance of collagen lattices made with arterial smooth muscle cells. J Cell Physiol. 1991;146:110-116.
38. Chesterman CN, Berndt MC. Platelet and vessel wall interaction and the genesis of atherosclerosis. Clin Haematol. 1986;15:323-353.
39. Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithrombotic and antilesion benefits without hemorrhagic risks bu inhibiting tissue factor pathway. Haemostasis. 1996;26(suppl 1):76-82.
40. Thompson WD, Smith EB, Stirk CM, Wang J. Fibrin degradation products in growth stimulatory extracts of pathological lesions. Blood Coagul Fibrinolysis. 1993;4:113-115.
41. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications to consequences of plaque rupture. J Am Coll Cardiol. 1994;23:1562-1569.
42. Bini A, Kudryk BJ. Fibrinogen in human atherosclerosis. Ann N Y Acad Sci. 1995;748:461-471.
43. Bini A, Kudryk BJ. Fibrinogen and fibrin in the arterial wall. Thromb Res. 1994;75:337-341.
44. Greco C, DiLoreto M, Ciavolella M, Banci M, Taurino M, Cerquetani E, Chiavarelli R, Naro F, Cusella-De Angelis G, Mele A, Scopinaro F, Marino B, Campa PP. Immunodetection of human atherosclerotic plaque with 125-I-labeled monoclonal antifibrin antibodies. Atherosclerosis. 1993;100:133-139.
45. Smith EB. Fibrin deposition and fibrin degradation products in atherosclerotic plaques. Thromb Res. 1994;75:329-335.
46. Bini A, Kudryk BJ. Fibrin and its derivatives in the normal and diseased vessel wall. Ann N Y Acad Sci. 1992;667:112-126.
47. Valenzuela R, Shainoff JR, DiBello PM, Urbanic DA, Anderson JM, Matsueda GR, Kudryk BJ. Immunoelectrophoretic and immunohistochemical characterizations of fibrinogen derivatives in atherosclerotic aortic intimas and vascular prosthesis pseudo-intimas. Am J Pathol. 1992;141:861-880.
48. Stirk CM, Kochhar A, Smith EB, Thompson WD. Presence of growthstimulating fibrin degradation products containing fragment E in human atherosclerotic plaques. Atherosclerosis. 1993;103:159-169.
49. Levenson J, Giral P, Razavian M, Gariepy J, Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 1995;15:1263-1268.
50. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Intern Med. 1993;118:956-963.
51. Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation. 1995;92:31-38.
52. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. Circulation. 1995;91:284-290.
53. Panchenko E, Dobrovolsky A, Davletov K, Titaeva E, Kravets A, Podinovskaya J, Karpov Y. D-dimer and fibrinolysis in patients with various degrees of atherosclerosis. Eur Heart J. 1995;16:38-42.
54. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B, for the Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 1995;333:764-769.
55. Serruys PW, Herrman J-PR, Simon R, Rutsch W, Bode C, Laarman G-J, Van Dijk R, Van Den Bos AA, Umans VAWM, Fox KAA, Close P, Deckers JW, for the Helvetica Investigators. A comparison of hirudun with heparin in the prevention of restensois after coronary angioplasty. N Engl J Med. 1995;333:757-763.
56. Richardson M, Kinlough-Rathbone RL, Groves HM, Jorgensen GL, Mustard JF, Moore S. Ultrastructural changes in re-endothelialized and non-endothelialized rabbit aortic neo-intima following re-injury with a balloon catheter. Br J Exp Pathol. 1984;65:597-611.
57. Taubman MB, Marmur JD, Rosenfield CL, Guha A, Nichtberger S, Nemerson Y. Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells. J Clin Invest. 1993;91:547-552.
58. Taubman MB. Tissue factor regulation in vascular smooth muscle: a summary of studies performed using in vivo and in vitro models. Am J Cardiol. 1993;72:55c-60c.
59. Salatti JA, Anton P, Nemerson Y, Sakariassen KS. Modulation of procoagulant activity of extracellular endothelial matrix by anti-tissue factor antibody and the synthetic peptide Arg-Gly-Asp-Val: experiments with flowing non-anticoagulated human blood. Blood Coagul Fibrinolysis. 1993;4:881-890.
60. Weiss HJ, Turitto VT, Baumgartner HR, Nemerson Y, Hofmann T. Evidence for the presence of tissue factor activity on subendothelium. Blood. 1989;73:968-975.
61. Weiss HJ, Hofmann T, Turitto VT, Nemerson Y. Further evidence on the presence of functional tissue factor activity on the subendothelium of normal human and rabbit arteries. Thromb Res. 1993;73:313-326.
62. Speidel CM, Eisenberg PR, Ruf W, Edgington TS, Abendschein DR. Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits. Circulation. 1995;92:3323-3330.
63. Contino PB, Andree HAM, Nemerson Y. Flow dependence of factor X activation by tissue factor-factor VIIa. J Physiol Pharmacol. 1994;45:81-90.
64. Le DT, Rapaport SI, Rao LV. Studies of the mechanism for enhanced cell surface factor VIIa/tissue factor activation of factor X on fibroblast monolayers after their exposure to N-ethylmaleimide. Thromb Haemost. 1994;72:848-855.